GLMD — Galmed Pharmaceuticals Share Price
0.000.00%
Last trade - 00:00- $3.61m
- -$12.12m
- 23
- 57
- 31
- 30
Growth & Value
| 12m Forecast Rolling | Industry | Market | |
|---|---|---|---|
| PE Ratio (f) | n/a | ||
| PEG Ratio (f) | n/a | ||
| EPS Growth (f) | n/a | ||
| Dividend Yield (f) | n/a | ||
| Valuation (ttm) | Industry | Market | |
|---|---|---|---|
| Price to Book Value | 0.16 | ||
| Price to Tang. Book | 0.16 | ||
| Price to Free Cashflow | n/a | ||
| Price to Sales | n/a | ||
| EV to EBITDA | n/a | ||
Shareholder Activity
| Type | Buy / Hold / Sell |
|---|---|
| Institutions | |
| Directors | |
| Community |
Guru Screens
Quality
| Name | Industry | Market | |
|---|---|---|---|
| Return on Capital | -45.46% | ||
| Return on Equity | -49.77% | ||
| Operating Margin | n/a | ||
Financial Summary
| Year End 31st Dec | Unit | 2020 | 2021 | 2022 | 2023 | 2024 | 2025E | 2026E | CAGR / Avg |
|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | $m | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
| Operating Profit | m | ||||||||
| Net Profit | m | ||||||||
| EPS Reported | |||||||||
| Diluted Normalised EPS | |||||||||
| EPS Growth | % | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
| PE Ratio | x | ||||||||
| PEG | |||||||||
| Profitability | |||||||||
| Operating Margin | % | ||||||||
| ROA | % | ||||||||
| ROCE | % | ||||||||
| ROE | % | ||||||||
| Cashflow | |||||||||
| Op. Cashflow ps | |||||||||
| Capex ps | |||||||||
| Free Cashflow ps | |||||||||
| Dividends | |||||||||
| Dividend ps | |||||||||
| Dividend Growth | % | ||||||||
| Dividend Yield | % | ||||||||
| Dividend Cover | x | ||||||||
| Balance Sheet | |||||||||
| Cash etc | m | ||||||||
| Working Capital | m | ||||||||
| NFA | m | ||||||||
| Net Debt | m | ||||||||
| Book Value | m | ||||||||
| Diluted Weighted Average Shares | m | ||||||||
| Book Value ps | |||||||||
Other Ratios
| Leverage (ttm) | Total | - Intang | + Pension |
|---|---|---|---|
| Gross Gearing | |||
| Net Gearing | |||
| Cash / Assets |
| Liquidity (ttm) | |
|---|---|
| Curr. Ratio | |
| Quick Ratio | |
| Interest Cov. | |
| Efficiency (ttm) | |
|---|---|
| Asset Turnover | |
| Recs Turnover | |
| Stock Turnover | |
Recent History
| Latest interim period vs. prior period | Industry | Market | |
|---|---|---|---|
| Sales Growth | |||
| EPS Growth | |||
| 3yr Compound Annual Growth Rate | Industry | Market | |
|---|---|---|---|
| Sales CAGR | |||
| EPS CAGR | |||
| DPS CAGR | |||
Profile Summary
Galmed Pharmaceuticals Ltd. is an Israel-based biopharmaceutical company dedicated to the development of therapeutics for the treatment of liver diseases. The Company is focused its research and development efforts on addressing unmet medical needs in the field of liver health. The Company's flagship product is Aramchol, a first-in-class synthetic fatty acid-bile acid conjugate molecule. Aramchol is aimed to be effective in the treatment of non-alcoholic steatohepatitis (NASH) in patients who are overweight or obese and have prediabetes or type II diabetes mellitus. The Company's drug aims to be efficient treatment of NASH, a chronic liver disease characterized by fat accumulation, inflammation, and fibrosis, which can lead to cirrhosis and liver cancer if left untreated.
Directors
- Allen Baharaff PRE (56)
- Yohai Stenzler CFO (38)
- Guy Nehemya COO (36)
- Liat Hayardeny CSO (54)
- David Sidransky LED (61)
- Marshall Heinberg DRC (63)
- Carol Brosgart IND (70)
- Shmuel Nir IND (59)
- Amir Poshinski IND (60)
- Last Annual
- December 31st, 2024
- Last Interim
- December 31st, 2024
- Incorporated
- July 31st, 2013
- Public Since
- March 13th, 2014
- No. of Shareholders
- 1
- No. of Employees
- 3
- Sector
- Biotechnology & Medical Research
- Industry
- Healthcare
- Exchange
- NASDAQ Capital Market
- Shares in Issue
- 2,258,034
- Address
- 16 Tiomkin Street, TEL AVIV-YAFO, 6578317
- Web
- https://www.galmedpharma.com
- Phone
- +972 36938448
- Auditors
- Brightman Almagor Zohar & Co
Upcoming Events for GLMD
Galmed Pharmaceuticals Ltd Annual Shareholders Meeting
Q2 2025 Galmed Pharmaceuticals Ltd Earnings Release
Q3 2025 Galmed Pharmaceuticals Ltd Earnings Release
Similar to GLMD
ABVC Biopharma
NASDAQ Capital Market
Acesis Holdings
NASDAQ Capital Market
Achieve Life Sciences
NASDAQ Capital Market
Aclarion
NASDAQ Capital Market
Acurx Pharmaceuticals
NASDAQ Capital Market
FAQ
What is the Galmed Pharmaceuticals share price?
As of Today at 20:45 UTC, shares in Galmed Pharmaceuticals are trading at $1.19. This share price information is delayed by 15 minutes.
How has the Galmed Pharmaceuticals share price performed this year?
Shares in Galmed Pharmaceuticals last closed at $1.19 and the price had moved by -75.15% over the past 365 days. In terms of relative price strength the Galmed Pharmaceuticals share price has underperformed the S&P500 Index by -77.88% over the past year.
What are the analyst and broker recommendations for Galmed Pharmaceuticals?
The overall consensus recommendation for Galmed Pharmaceuticals is Hold. You can view the full broker recommendation list by unlocking its StockReport.
Find out moreWhat is the Galmed Pharmaceuticals dividend yield?
Galmed Pharmaceuticals does not currently pay a dividend.
Does Galmed Pharmaceuticals pay a dividend?
Galmed Pharmaceuticals does not currently pay a dividend.
When does Galmed Pharmaceuticals next pay dividends?
Galmed Pharmaceuticals does not currently pay a dividend.
How do I buy Galmed Pharmaceuticals shares?
To buy shares in Galmed Pharmaceuticals you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.
What is the market cap of Galmed Pharmaceuticals?
As of the previous close price of $1.19, shares in Galmed Pharmaceuticals had a market capitalisation of $2.69m.
Where are Galmed Pharmaceuticals shares listed?
Here are the trading details for Galmed Pharmaceuticals:
- Country of listing: United States
- Exchange: NAQ
- Ticker Symbol: GLMD
What kind of share is Galmed Pharmaceuticals?
Based on an overall assessment of its quality, value and momentum Galmed Pharmaceuticals is currently classified as a Value Trap. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.
Is there a Galmed Pharmaceuticals share price forecast for 2025?
The analyst consensus target price for shares in Galmed Pharmaceuticals is $12.00. That is 908.4% above the last closing price of $1.19.
Analysts covering Galmed Pharmaceuticals currently have a consensus Earnings Per Share (EPS) forecast of -$3.26 for the next financial year.
Find out moreWhat is the trend in the Galmed Pharmaceuticals share price?
An important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like Galmed Pharmaceuticals. Over the past six months, its share price has underperformed the S&P500 Index by -59.83%.
As of the last closing price of $1.19, shares in Galmed Pharmaceuticals were trading -61.12% below their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.
What is the Galmed Pharmaceuticals PE Ratio?
The Galmed Pharmaceuticals PE ratio based on its reported earnings over the past 12 months is null. The shares last closed at $1.19.
The PE ratio (or price-to-earnings ratio) is the one of the most popular valuation measures used by stock market investors. It is calculated by dividing a company's price per share by its earnings per share.
The PE ratio can be seen as being expressed in years, in the sense that it shows the number of years of earnings which would be required to pay back the purchase price, ignoring inflation. So in general terms, the higher the PE, the more expensive the stock is.
Who are the key directors of Galmed Pharmaceuticals?
Galmed Pharmaceuticals' management team is headed by:
- Allen Baharaff - PRE
- Yohai Stenzler - CFO
- Guy Nehemya - COO
- Liat Hayardeny - CSO
- David Sidransky - LED
- Marshall Heinberg - DRC
- Carol Brosgart - IND
- Shmuel Nir - IND
- Amir Poshinski - IND